Investigation of A-ECM for the Correction of Soft Tissue Defects

PHASE1UnknownINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

March 31, 2014

Primary Completion Date

June 30, 2015

Study Completion Date

August 31, 2015

Conditions
Disorder of Soft Tissue of Body Wall Region
Interventions
DEVICE

Adipose-derived ECM

Each syringe of adipose-derived ECM will hold 2mL and will be for single use only. Up to 3 syringes (6mL total) may be used for each patient. Injections will be made under local anesthesia and sterile conditions using a 23-gauge needle. All injections will be performed in an outpatient clinic setting at study site by the principal investigator who will determine the method, depth, and volume of each implant. Decellularized adipose tissue-derived matrix will be infiltrated into the defect and the underlying musculature as well as the subcutaneous tissue surrounding the defect, with the goal of creating a smooth transition from surrounding structures to the filled defect. This will be performed using a series of multiple punctures or a single puncture with a fanning or threading technique. After the injection is completed, the treatment area will be massaged to conform to the contour of the surrounding tissue and ice will be applied as needed for swelling.

Trial Locations (1)

21204

Cosmetic Surgery Center of Maryland, Towson

Sponsors
All Listed Sponsors
lead

Aegeria Soft Tissue LLC

INDUSTRY